3 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 3, Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Recruiting 2, Completed 1 |
Follow Recurrent Solid Tumor: new trials by email Literature Review of Recurrent Solid Tumor trials Research Report on Recurrent Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Validation of the G8 Screening Tool for Prognostic Assessment of Frailty and Early Mortality in Elderly Individuals With Cancer: Prospective Cohort Study in Brazil Solid Tumor, Metastatic Solid Tumor | Not yet recruiting | Latin American Cooperative Oncology Group | 250 | 2026-09-01 | 2026-08-26 | |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors LY4052031, Pembrolizumab - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Recruiting | Eli Lilly and Company | 460 | 2024-07-01 | 2026-10-22 |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors LY4101174 - Metastatic Solid Tumor, Recurrent Solid Tumor | Phase 1 | Active not recruiting | Eli Lilly and Company | 490 | 2024-03-05 | 2026-05-22 |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer [177Lu]Lu-SN201 - Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Spago Nanomedical AB | 90 | 2023-12-06 | 2025-11-20 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion - Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Completed | TyrNovo Ltd. | 52 | 2020-09-03 | 2024-09-19 |
| Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma Geptanolimab Injection 1mg/kg, Geptanolimab Injection 3mg/kg, Geptanolimab Injection 10mg/kg - Advanced Solid Tumor, Recurrent Solid Tumor | Phase 1 | Unknown | Genor Biopharma Co., Ltd. | 72 | 2017-10-19 | 2021-08-16 |
| ODSH + ICE Chemotherapy in Pediatric Solid Tumors ODSH - Recurrent Solid Tumor, Refractory Solid Tumor | Phase 1 | Terminated | New York Medical College | 4 | 2015-01-01 | 2017-12-22 |
Neoplasm Metastasis (5) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Neoplasms (2) · Neuroblastoma (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Sarcoma (2) · Triple Negative Breast Neoplasms (2) · Ureteral Neoplasms (2) · Urinary Bladder Neoplasms (2) · Urologic Neoplasms (2) · Uterine Cervical Neoplasms (2)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Neoplastic Processes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Carcinoma (3) · Carcinoma, Squamous Cell (3)
N-desulfated,2-O,3-O-desulfated heparin (1) · Temozolomide (1) · irinotecan sucrosofate (1) · pembrolizumab (1) · talazoparib (1)
Eli Lilly and Company (2) · Genor Biopharma Co., Ltd. (1) · Latin American Cooperative Oncology Group (1) · New York Medical College (1) · Spago Nanomedical AB (1) · St. Jude Children's Research Hospital (1) · TyrNovo Ltd. (1)
United States (5) · Australia (3) · China (3) · France (2) · Japan (2) · Spain (2) · Belgium (1) · Brazil (1) · Canada (1) · Israel (1) · South Korea (1) · United Kingdom (1)
Kim Taubman (1) · Ludmila Koch (1) · Michael Schickler, PhD (1) · Mitchell Cairo, MD (1) · Sara Federico, MD (1) · Yuankai Shi, Doctor (1)
2023 (1)